Critical study of 5 per cent guanethidine in ocular manifestations of Graves's disease.
Assessment was made of 5% local guanethidine in treating eye manifestations in euthyroid patients with either treated thyrotoxicosis or ophthalmic Graves's disease. In a double-blind crossover study guanethidine caused greater improvement in lid retraction than a control solution. A long-term study showed that this improvement was maintained. A much lower incidence of side-effects was noted with 5% guanethidine than with 10% solution.
D002986:Clinical Trials as Topic; D005132:Eye Manifestations; D005141:Eyelid Diseases / Q000188:drug therapy; D005260:Female; D006111:Graves Disease / Q000188:drug therapy*; D006145:Guanethidine / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy*; D007429:Intraocular Pressure; D008297:Male; D010919:Placebos
D010919:Placebos; D006145:Guanethidine